<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723762</url>
  </required_header>
  <id_info>
    <org_study_id>Valproic Acid-Albumin</org_study_id>
    <nct_id>NCT00723762</nct_id>
  </id_info>
  <brief_title>Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients</brief_title>
  <official_title>Valproic Acid-associated Hypoalbuminemia in Medically Fragile Pediatric and Young Adult Patients in a Long Term Care Facility Part 1: Potential Mechanism for Decreased Albumin Synthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akron Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akron Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate potential mechanisms of valproic acid-associated
      low serum albumin in medically fragile pediatric and young adult epileptic patients of a
      long-term care facility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Valproic acid (VPA) is a long-chain fatty acid frequently used as an antiepileptic agent in
      pediatric and adult seizure patients. Other adverse effects that have been associated with
      VPA use include hepatic steatosis, altered mitochondrial function and decreased
      concentrations of serum proteins. The exact mechanism or mechanisms by which VPA induces
      these associated adverse drug effects are not fully understood though multiple theories have
      been postulated including impaired vesicle transport within the hepatocyte, inhibition of
      hepatic synthetic metabolic pathways and renal protein loss. Decreased serum albumin
      concentrations with concomitant VPA use have been identified in multiple studies. Albumin
      synthesis is sensitive to tryptophan concentrations (other amino acids are also able to
      stimulate albumin synthesis), oncotic pressure near the synthetic site, and energy supply
      while albumin release from the hepatocyte is sensitive to intrahepatocellular potassium
      concentrations. Based on available literature, VPA appears to inhibit an enzyme(s) either
      directly or indirectly involved with albumin synthesis or albumin gene expression. VPA is
      known to inhibit the urea cycle, including patients with ornithine-transcarbamylase (OTC)
      deficiency, possibly by inhibiting mitochondrial carbamoyl-phosphate synthase. Oratz et al
      discussed the potential correlation between the urea cycle and albumin synthesis identified
      after the administration of various amino acids increased both albumin and urea synthesis.
      Ornithine is an intermediate amino acid within the urea cycle and it is also a precursor to
      polyamines which have been shown to increase the degree of aggregation of polysomes,
      responsible for protein synthesis, bound to the endoplasmic reticulum. Thus, VPA may
      indirectly inhibit protein synthesis by interfering with the urea cycle leading to decreased
      ornithine concentrations and subsequently a decrease in polyamine concentrations and a
      decrease in the number of bound polysomes resulting in alterations in albumin synthesis and
      release. The purpose of this study is to investigate potential mechanisms of VPA-associated
      hypoalbuminemia in medically fragile pediatric and young adult epileptic patients of a
      long-term care facility.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be serum albumin concentrations at baseline in the patients receiving VPA.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome variables will include serum amino acid concentrations, total protein, AST, ALT, alkaline phosphatase, ammonia, BUN, and sCr and urine albumin, protein, and urea.</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hypoalbuminemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Resident of Hattie Larlham long-term care facility receiving VPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Control AED patients will be recruited based on similar AED regimens excluding VPA, length of time on AED (number of months to &gt;1 year), age, and gender; one control patient per VPA patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Control non-AED patients will be recruited based on age and gender; one control patient per VPA patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Specimen collection</intervention_name>
    <description>A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and urine samples from patients receiving VPA.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Medically fragile residents of the Hattie Larlham Long Term Care Facilit.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resident of Hattie Larlham long-term care facility receiving VPA for &gt; 3 months at the
             start of the study

          -  Resident of Hattie Larlham long-term care facility matched to a resident receiving VPA
             for &gt; 3 month based on concomitant AED, length of time on AED, age, and gender

          -  Resident of Hattie Larlham long-term care facility not receiving AED matched to a
             resident receiving VPA for &gt; 3 month based on age and gender

        Exclusion Criteria:

          -  Received albumin products within the past 1 month

          -  Receiving VPA for &lt; 3 months or discontinuation of VPA therapy within the past four
             weeks

          -  Medical need for specific protein supplementation

          -  Diagnosed with protein-losing nephropathy or enteropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Reed, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akron Children's Hospital Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha Blackford, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Akron Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Grossberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hattie Larlham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hattie Larlham Center for Children with Disabilities</name>
      <address>
        <city>Mantua</city>
        <state>Ohio</state>
        <zip>44255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Attilakos A, Voudris KA, Katsarou E, Prassouli A, Mastroyianni S, Garoufi A. Transient decrease in serum albumin concentrations in epileptic children treated with sodium valproate monotherapy. Clin Neuropharmacol. 2007 May-Jun;30(3):145-9.</citation>
    <PMID>17545749</PMID>
  </reference>
  <reference>
    <citation>Hauser E, Seidl R, Freilinger M, Male C, Herkner K. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev. 1996 Mar-Apr;18(2):105-9.</citation>
    <PMID>8733899</PMID>
  </reference>
  <reference>
    <citation>Rugino TA, Janvier YM, Baunach JM, Bilat CA. Hypoalbuminemia with valproic acid administration. Pediatr Neurol. 2003 Nov;29(5):440-4.</citation>
    <PMID>14684241</PMID>
  </reference>
  <reference>
    <citation>Oratz M, Rothschild MA, Schreiber SS, Burks A, Mongelli J, Matarese B. The role of the urea cycle and polyamines in albumin synthesis. Hepatology. 1983 Jul-Aug;3(4):567-71.</citation>
    <PMID>6407956</PMID>
  </reference>
  <reference>
    <citation>Karikas GA, Schulpis KH, Bartzeliotou A, Karakonstantakis T, Georgala S, Kanavaki I, Demetriou E, Papassotiriou I. Lipids, lipoproteins, apolipoproteins, selected trace elements and minerals in the serum of children on valproic acid monotherapy. Basic Clin Pharmacol Toxicol. 2006 Jun;98(6):599-603.</citation>
    <PMID>16700824</PMID>
  </reference>
  <reference>
    <citation>Castro-Gago M, Rodrigo-Saez E, Novo-Rodriguez I, Cami√±a MF, Rodriguez-Segade S. Hyperaminoacidemia in epileptic children treated with valproic acid. Childs Nerv Syst. 1990 Dec;6(8):434-6.</citation>
    <PMID>2095300</PMID>
  </reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michael Reed, Pharm.D.</name_title>
    <organization>Akron Children's Hospital</organization>
  </responsible_party>
  <keyword>Valproic acid</keyword>
  <keyword>Urea cycle</keyword>
  <keyword>Ornithine</keyword>
  <keyword>Valproate</keyword>
  <keyword>Side effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoalbuminemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

